US government does not own any remdesivir patents, GAO report finds
The US federal government’s contributions to research on Gilead’s Covid-19 antiviral drug remdesivir did not result in any patent rights because the research did not create new inventions, the Government Accountability Office said in a report on Wednesday afternoon.
The report settles a longstanding dispute over whether the government might be co-inventors of remdesivir, which has lingered since before former California attorney general Xavier Becerra (who’s now Biden’s HHS secretary) led a group of other AGs last summer in calling on the government to intervene and lower the more than $3,000 price tag for remdesivir because of the government’s significant contributions to remdesivir.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters